Literature DB >> 2895517

Prevalence of cytomegalovirus antibody in hemophiliacs and homosexuals infected with human immunodeficiency virus type 1.

J B Jackson1, A Erice, J A Englund, J R Edson, H H Balfour.   

Abstract

We determined the prevalence of antibody to cytomegalovirus (CMV) in the sera of non-homosexual hemophilia patients and homosexual men infected with the human immunodeficiency virus type 1 (HIV-1). CMV antibody testing by latex agglutination revealed 33 of 58 HIV-1 infected hemophiliacs (57%) were antibody-positive compared with 54 of 54 HIV-1 infected asymptomatic non-hemophiliac homosexuals (100%) (p less than .001). Nine of 15 hemophiliacs (60%) with symptomatic HIV-1 infection were CMV antibody-positive. We also tested 22 HIV-1 antibody-negative hemophiliacs who had received non-heat treated factor concentrates. 14 of these 22 (64%) were CMV antibody-positive compared with 57% of HIV-1 antibody-positive hemophiliacs. We conclude 1) there is little correlation between transmission of HIV-1 and CMV by factor concentrates, 2) the presence of CMV antibody does not appear to be associated with clinical stage of HIV-1 infection in hemophiliacs, and 3) there may be a significant number of CMV antibody-negative hemophiliacs with HIV-1 infection at risk for primary infection and subsequent disease if CMV seronegative blood products are not provided for future transfusions.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2895517     DOI: 10.1046/j.1537-2995.1988.28288179029.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  9 in total

1.  A role for cytomegalovirus-specific CD4+CX3CR1+ T cells and cytomegalovirus-induced T-cell immunopathology in HIV-associated atherosclerosis.

Authors:  Karim Sacre; Peter W Hunt; Priscilla Y Hsue; Ekaterina Maidji; Jeffrey N Martin; Steven G Deeks; Brigitte Autran; Joseph M McCune
Journal:  AIDS       Date:  2012-04-24       Impact factor: 4.177

2.  Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030.

Authors:  D A Wohl; M A Kendall; J Andersen; C Crumpacker; S A Spector; J Feinberg; B Alston-Smith; S Owens; S Chafey; M Marco; S Maxwell; N Lurain; D Jabs; C Benson; P Keiser; M A Jacobson
Journal:  HIV Clin Trials       Date:  2009 May-Jun

3.  CMV retinopathy in the antiretroviral therapy era: prevention, diagnosis, and management.

Authors:  Lisa Barrett; Sharon Walmsley
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

4.  The effect of CMV infection on progression of human immunodeficiency virus disease is a cohort of haemophilic men followed for up to 13 years from seroconversion.

Authors:  C A Sabin; A N Phillips; C A Lee; G Janossy; V Emery; P D Griffiths
Journal:  Epidemiol Infect       Date:  1995-04       Impact factor: 2.451

5.  Progression of HIV disease in a haemophilic cohort followed for 11 years and the effect of treatment.

Authors:  C A Lee; A N Phillips; J Elford; G Janossy; P Griffiths; P Kernoff
Journal:  BMJ       Date:  1991-11-02

6.  Strong trans activation of the human cytomegalovirus major immediate-early enhancer by p40tax of human T-cell leukemia virus type I via two repetitive tax-responsive sequence elements.

Authors:  H Moch; D Lang; T Stamminger
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

7.  Relative seroprevalence of human herpes viruses in patients with chronic lymphocytic leukaemia.

Authors:  C Steininger; L Z Rassenti; K Vanura; K Eigenberger; U Jäger; T J Kipps; C Mannhalter; S Stilgenbauer; T Popow-Kraupp
Journal:  Eur J Clin Invest       Date:  2009-06       Impact factor: 4.686

Review 8.  Monocytes as regulators of inflammation and HIV-related comorbidities during cART.

Authors:  Joshua J Anzinger; Tiffany R Butterfield; Thomas A Angelovich; Suzanne M Crowe; Clovis S Palmer
Journal:  J Immunol Res       Date:  2014-06-12       Impact factor: 4.818

9.  A rare case of CMV pneumonia in HIV-infection.

Authors:  Kai Chin Poh; Shuwei Zheng
Journal:  Respir Med Case Rep       Date:  2019-10-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.